3,268 results on '"Stein, Mark"'
Search Results
252. Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors
253. Circulating Tumor Cell Subtypes and T-cell Population as Prognostic Biomarkers to Combination Immunotherapy in Metastatic Genitourinary Cancer Patients
254. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium
255. New Frontiers in Subcutaneous Immunoglobulin Treatment
256. Pharmacokinetics of Subcutaneous IgPro20 in Patients with Primary Immunodeficiency
257. Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary Immunodeficiency Disease
258. OTTOMAN BUREAUCRATIC COMMUNICATION: An Example From Uyvar, 1673
259. The Pharmacogenomic Era: Promise for Personalizing Attention Deficit Hyperactivity Disorder Therapy
260. Tolerability of a New 10% Liquid Immunoglobulin for Intravenous Use, Privigen®, at Different Infusion Rates
261. Efficacy, Pharmacokinetics, Safety, and Tolerability of Flebogamma® 10% DIF, a High-Purity Human Intravenous Immunoglobulin, in Primary Immunodeficiency
262. Progress and Promise of Attention-Deficit Hyperactivity Disorder Pharmacogenetics
263. Originalism and original exclusions.
264. Long term safety, efficacy, tolerability, and pharmacokinetics of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin G: a phase 3 extension study in patients with primary immunodeficiencies.: 193E.
265. Efficacy, safety and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin in adult subjects with primary immunodeficiency enrolled in a Phase 3 Study.: 190E.
266. Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion
267. Safety and Efficacy of Privigen®, a Novel 10% Liquid Immunoglobulin Preparation for Intravenous Use, in Patients with Primary Immunodeficiencies
268. The domestic violence clause in 'new originalist' theory.
269. Nussbaum: a utilitarian critique.
270. Integrative Learning and Simulating Revolution and Protest in the Middle East.
271. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer
272. Task-related excitatory/inhibitory ratios in the fronto-striatal circuitry predict attention control deficits in attention-deficit/hyperactivity disorder
273. Novel Home Direct-to-Consumer Telehealth Solutions for Children with Mental Health Disorders
274. Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer
275. A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti–PD-1) in patients with metastatic castration-resistant prostate cancer.
276. The SPARC-1 trial: A phase I study of neoadjuvant combination interleukin-1 beta and PD-1 blockade in localized clear cell renal cell carcinoma.
277. Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.
278. Phase II trial of cytoreductive surgery in kidney cancer plus immunotherapy (nivolumab) and targeted kinase inhibition (cabozantinib) (Cyto-KIK).
279. Phase II clinical study of concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: Results for primary analyses and survival. BTCRC-GU15-023.
280. EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.
281. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
282. Innovation Will be Endless
283. 8 Ways That Remote Learning Will Shape the Future
284. Efficacy, Safety and Tolerability of a New 10% Liquid Intravenous Immune Globulin [IGIV 10%] in Patients with Primary Immunodeficiency
285. Toxicity and the unconscious experiences of the body at the employee-customer interface
286. Individual and joint effects of metformin and statins on mortality among patients with high-risk prostate cancer.
287. Searching for Unclaimed Assets Could Pay Off
288. Cortisol is inversely correlated with aggression for those boys with attention deficit hyperactivity disorder who retain their reactivity to stress
289. Erratum to: Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency
290. Hypertext and the identity link
291. An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth
292. Precision Medicine Care in ADHD: The Case for Neural Excitation and Inhibition
293. Ideology in Postcolonial Texts and Contexts
294. Clinical immunology in practice, new opportunities
295. Generic top-level domain expansion brings new opportunities, risks for business owners
296. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study
297. The Security Council, the International Criminal Court, and the crime of aggression: how exclusive is the Security Council's power to determine aggression?
298. The Othello conundrum: the inner contagion of leadership
299. Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
300. Abstract PO-046: Single-cell profiling of tumor evolution and complex immune infiltrate induced by ADT and PD-1 blockade in metastatic hormone-sensitive prostate cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.